Cargando…

Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice

While the autoimmune character of T1D (type 1 diabetes) is being challenged, it is currently recognized that inflammation plays a key role in its development. We hypothesized that glucotoxicity could contribute to β-cell mass destruction through participation in islet inflammation. We evaluated the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Daems, Caroline, Welsch, Sophie, Boughaleb, Hasnae, Vanderroost, Juliette, Robert, Annie, Sokal, Etienne, Lysy, Philippe A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6701376/ https://www.ncbi.nlm.nih.gov/pubmed/31467926 http://dx.doi.org/10.1155/2019/2813489

Ejemplares similares

Combined Algorithm-Based Adaptations of Insulin Dose and Carbohydrate Intake During Exercise in Children With Type 1 Diabetes: Results From the CAR2DIAB Study
por: Lysy, Philippe Antoine, et al.
Publicado: (2021)

Characterization, evolution and risk factors of diabetes and prediabetes in a pediatric cohort of renal and liver transplant recipients
por: Welsch, Sophie, et al.
Publicado: (2023)

Effect of Empagliflozin, a Selective Sodium-Glucose Cotransporter 2 Inhibitor, on Kidney and Peripheral Nerves in Streptozotocin-Induced Diabetic Rats
por: Lee, Kyung Ae, et al.
Publicado: (2018)

Biological Assessment of the NO-Dependent Endothelial Function
por: Boughaleb, Hasnae, et al.
Publicado: (2022)

Empagliflozin Attenuates Myocardial Sodium and Calcium Dysregulation and Reverses Cardiac Remodeling in Streptozotocin-Induced Diabetic Rats
por: Lee, Ting-I, et al.
Publicado: (2019)

Effects of empagliflozin on the expression of kisspeptin gene and reproductive system function in streptozotocin-induced diabetic male rats
por: Dana, Parisa, et al.
Publicado: (2022)

The Sodium-Glucose Co-Transporter 2 Inhibitor Empagliflozin Improves Diabetes-Induced Vascular Dysfunction in the Streptozotocin Diabetes Rat Model by Interfering with Oxidative Stress and Glucotoxicity
por: Oelze, Matthias, et al.
Publicado: (2014)

Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats
por: Shao, Qingmiao, et al.
Publicado: (2019)

The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic β-Cell Mass and Glucose Homeostasis in Type 1 Diabetes
por: Cheng, Sam Tsz Wai, et al.
Publicado: (2016)

Impact of diabetes duration on left ventricular mass regression with empagliflozin
por: Moroney, Michael, et al.
Publicado: (2023)

Soybean isoflavone extract improves glucose tolerance and raises the survival rate in streptozotocin-induced diabetic rats
por: Shim, Jee-Youn, et al.
Publicado: (2007)

Pooled Safety and Tolerability Analysis of Empagliflozin in Patients with Type 2 Diabetes Mellitus
por: Kinduryte Schorling, Ona, et al.
Publicado: (2020)

Comparison of the Pharmacokinetics, Safety, and Tolerability of Two Empagliflozin Formulations in Healthy Korean Subjects
por: Jiang, Xu, et al.
Publicado: (2023)

Characterization and risk factors of hyperglycaemia during treatment of childhood hematologic malignancies
por: Welsch, Sophie, et al.
Publicado: (2021)

Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure
por: Boorsma, Eva M., et al.
Publicado: (2020)

Empagliflozin alleviates renal inflammation and oxidative stress in streptozotocin-induced diabetic rats partly by repressing HMGB1-TLR4 receptor axis
por: Ashrafi Jigheh, Zahra, et al.
Publicado: (2019)

Pharmacokinetic and Pharmacodynamic Profile of Empagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor
por: Scheen, André J.
Publicado: (2014)

Differential cardiovascular profiles of sodium-glucose cotransporter 2 inhibitors: critical evaluation of empagliflozin
por: Sanon, Vani P, et al.
Publicado: (2017)

Renal and Glucose-Lowering Effects of Empagliflozin and Dapagliflozin in Different Chronic Kidney Disease Stages
por: Lin, Yi-Hsuan, et al.
Publicado: (2019)

Acute interstitial nephritis due to sodium-glucose co-transporter 2 inhibitor empagliflozin
por: Ryan, Rebecca, et al.
Publicado: (2020)

Circadian Control of the Daily Plasma Glucose Rhythm: An Interplay of GABA and Glutamate
por: Kalsbeek, Andries, et al.
Publicado: (2008)

Left ventricular mass predicts cardiac reverse remodelling in patients treated with empagliflozin
por: Puar, Pankaj, et al.
Publicado: (2023)

Integration of Routine Parameters of Glycemic Variability in a Simple Screening Method for Partial Remission in Children with Type 1 Diabetes
por: Nielens, Nina, et al.
Publicado: (2018)

Effects of treadmill running on extracellular basal levels of glutamate and GABA at dentate gyrus of streptozotocin-induced diabetic rats
por: Reisi, Parham, et al.
Publicado: (2010)

Population Pharmacokinetics and Exposure–Response (Efficacy and Safety/Tolerability) of Empagliflozin in Patients with Type 2 Diabetes
por: Baron, Kyle T., et al.
Publicado: (2016)

Empagliflozin Ammeliorates High Glucose Induced-Cardiac Dysfuntion in Human iPSC-Derived Cardiomyocytes
por: Ng, Kwong-Man, et al.
Publicado: (2018)

Empagliflozin in type 1 diabetes
por: Mathieu, Chantal, et al.
Publicado: (2019)

Anti-inflammatory potential of Empagliflozin
por: Pirklbauer, Markus
Publicado: (2021)

Drug eruption associated with empagliflozin
por: Yau, Kevin, et al.
Publicado: (2022)

Role of GABAB Receptor and L-Arg in GABA-Induced Vasorelaxation in Non-diabetic and Streptozotocin-Induced Diabetic Rat Vessels
por: Kharazmi, Fatemah, et al.
Publicado: (2015)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of Empagliflozin in Patients with Type 2 Diabetes Mellitus
por: Heise, Tim, et al.
Publicado: (2013)

Amiodarone-induced thyroid dysfunction in children: insights from the THYRAMIO study
por: Montenez, Sarah, et al.
Publicado: (2021)

GABA release by hippocampal astrocytes
por: Le Meur, Karim, et al.
Publicado: (2012)

Glucose lowering by SGLT2-inhibitor empagliflozin accelerates atherosclerosis regression in hyperglycemic STZ-diabetic mice
por: Pennig, Jan, et al.
Publicado: (2019)

Effects of the sodium‐glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure
por: Kolwelter, Julie, et al.
Publicado: (2021)

Multi-omics analysis reveals attenuation of cellular stress by empagliflozin in high glucose-treated human cardiomyocytes
por: Scisciola, Lucia, et al.
Publicado: (2023)

1-deoxynojirimycin inhibits glucose absorption and accelerates glucose metabolism in streptozotocin-induced diabetic mice
por: Li, You-Gui, et al.
Publicado: (2013)

Empagliflozin: Not just a glorified diuretic
por: John, Mathew
Publicado: (2016)

Impact of empagliflozin on diabetic kidney disease
por: Koya, Daisuke
Publicado: (2017)

Empagliflozin in Patients with Chronic Kidney Disease
por: Herrington, William G., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_c412vrkqk41fgcgdlki0ovv4op